Related Experiment Video
Updated: May 21, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Revealing neuroendocrine transformation in gynecological cancers through genomic analysis
Ann Oluloro1, David L Wells2, Charles K Childers2
1Division of Gynecological Oncology, University of Washington, Seattle, WA, USA.
Abstract:
Neuroendocrine transformation (NT) in cancers, typically observed under the selective pressure of targeted therapies, involves lineage plasticity where adenocarcinomas adopt neuroendocrine characteristics while retaining the molecular alterations of their original histology. This phenomenon, well-documented in prostate and lung cancers, has not been observed in gynecological malignancies until now. We present two pivotal cases involving primary ovarian and uterine cancers that developed neuroendocrine carcinomas post-treatment. Initially presumed to be independent primaries, comprehensive next-generation sequencing technologies, including UW-OncoPlex and BROCA panels, were used to establish a clonal relationship between the primary tumors and their respective neuroendocrine metastases. This report provides the first documented instances of NT in gynecological cancers, indicating that it may be a more widespread resistance mechanism than previously recognized. Routine re-biopsy and early integration of advanced molecular diagnostics into clinical practice will identify NT and provide insights into pathogenesis and eventual therapeutic options.
Insights
Neuroendocrine transformation (NT) is a cancer adaptation seen in prostate and lung cancers. This study documents the first cases of NT in ovarian and uterine cancers, revealing it as a potential resistance mechanism.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Pathology
Background:
- Neuroendocrine transformation (NT) is a known adaptive resistance mechanism in cancers like prostate and lung, driven by targeted therapies.
- This phenomenon, characterized by adenocarcinomas acquiring neuroendocrine features while retaining original molecular alterations, has not been previously documented in gynecological malignancies.
Purpose of the Study:
- To report the first documented cases of neuroendocrine transformation in primary ovarian and uterine cancers.
- To investigate the clonal relationship between primary gynecological tumors and their neuroendocrine metastases using advanced molecular techniques.
Main Methods:
- Case study of two patients with primary ovarian and uterine cancers.
- Comprehensive next-generation sequencing using UW-OncoPlex and BROCA panels.
- Molecular profiling to establish clonal origin of primary and metastatic tumors.
Main Results:
- Two pivotal cases of primary ovarian and uterine cancers developing neuroendocrine carcinomas post-treatment are presented.
- Next-generation sequencing confirmed a clonal relationship between the primary tumors and their neuroendocrine metastases.
- This study provides the first evidence of NT in gynecological cancers.
Conclusions:
- Neuroendocrine transformation is a newly identified phenomenon in gynecological cancers, suggesting it may be a more common resistance mechanism than previously thought.
- Routine re-biopsy and molecular diagnostics are crucial for identifying NT in gynecological malignancies.
- Further research into NT pathogenesis and therapeutic strategies is warranted.
